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Abstract Stem cell transplantation following AMI has
shown promise for the repair or reduction of the amount of
myocardial injury. There is some evidence that these
treatment effects appear to be directly correlated to cell
residence time. This study aims to assess the effects of
(a) the timing of stem cell injection following myocardial
infarction, and (b) flow milieu, on cell residence times at
the site of transplantation by comparing three time points
(day of infarction, week 1 and week 4–5), and two models
of acute myocardial infarction (sustained occlusion or
reperfusion). Twenty-one dogs received 2 injections of 30
million endothelial progenitor cells. The first injections
were administered by epicardial (n = 8) or endocardial
injection (n = 13) either on the day of infarction (n = 15)
or at 1 week (n = 6). The second injections were admin-
istered by only endocardial injection (n = 18) 4 weeks
following the first injection. Cell clearance half-lives were
comparable between early and late injections. However,
transplants into sustained occlusion infarcts resulted in
slower cell clearance 77.1 ± 6.1 (n = 18) versus reper-
fused 59.4 ± 2.9 h (n = 21) p = 0.009. Sustained occlu-
sion infarcts had longer cell retention in comparison to
reperfusion whereas the timing of injection did not affect
clearance rates. If the potential for myocardial regeneration
associated with cell transplantation is, at least in part,
linked to cell residence times, then greater benefit may be
observed with transplants into infarcts associated with
persistent coronary artery occlusion.
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Abbreviations
AMI Acute myocardial infarction
CT Computed tomography
EPC Endothelial progenitor cell
LV Left ventricular
SEM Standard error of the mean
SPECT Single photon emission computed tomography
Introduction
Cardiovascular disease remains a major cause of death and
disability with its contribution to the world’s burden of
disease projected to rise [1]. Acute myocardial infarction
(AMI) leads to irreversible myocardial fibrosis, and
adverse left ventricular (LV) remodelling. Based on early
reports from small animal models [2–6] there has been
great interest for cell therapies to a) reduce myocardial
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injury and b) regenerate new myocardium. Endothelial
progenitor cells (EPCs) have been shown to have potential
in promoting cardiac repair through angiogenesis [7–10].
Early non-randomized clinical studies suggested bene-
ficial effects on global LV function [11–13] although
subsequent trials produced inconsistent results [14–17].
However, recent meta-analyses [18, 19] demonstrated
significant, albeit modest, improvements in ejection frac-
tion. Species differences in the absolute size of the infarcts
and the nature and timing of the inflammatory response
[20] may explain the variation in the degree of improve-
ment between small animal and clinical studies. Amongst
other factors, cell residence time has been shown to play an
important role in influencing myocardial repair [21]. As
well, direct intramyocardial delivery of cells has been
explored for both endocardial (catheter based) and epicar-
dial (full or mini-thorocotomy-based) injections with high
and equivalent initial cell retention rates [22–25].
The current study was designed to determine the factors
that affect cell residence time following direct injection,
with infarcts comparable to patients in size and with a
similar inflammatory response [20], with clinically appli-
cable and validated imaging tools i.e. cell labelling
(Indium-tropolone) and imaging (SPECT) [26, 27], and cell
injection techniques (endocardial and epciardial). In this
study, we examine cell clearance rates a) on the day of
infarction, b) at 1 week and c) 4 weeks following the first
injection, in two models of AMI; a sustained occlusion
model, and a 2-h occlusion-reperfusion model.
Methods
Cell preparation
Autologous EPCs were isolated from the peripheral blood
by density gradient centrifugation as described by He et al.,
and expanded to 30 million cells over 8 weeks, [28]. Cells
were labeled with 111In-tropolone at 0.1 Bq/cell, a dose not
affecting viability or proliferation [29].
Surgical preparation
Twenty-one 20–24 kg adult female bred-for-research
hounds were used. All procedures were approved by the
Animal Care Committee of the University of Western
Ontario, and performed according to the Guide of the
Animal Care and Use of Experimental Animals of the
Canadian Council on Animal Care and Use of Laboratory
Animals, National Research Council. The results from 14
of these animals, comparing cell retention and clearance
rates for endocardial versus epicardial delivery, had pre-
viously been reported and the surgical methods described
[25]. Anesthesia was induced with propofol and maintained
with isoflurane (2 %). Briefly, a myocardial infarction was
induced by placing a snare ligature around the left anterior
descending coronary artery distal to the first diagonal
branch. In 11 animals, the snare was released 2 h following
occlusion, and in the remaining 10 animals, the artery was
tied off permanently. An additional 3 dogs, 2 with reper-
fusion, and 1 without, died suddenly within days following
infarction, and their clearance times could not be measured.
Timing of injection
Eight animals received direct epicardial injections at tho-
racotomy, 4 h following occlusion. The remaining 13
animals received endocardial injections using a LV cath-
eter. Seven of these endocardial injections occurred 4 h
after the induction of the myocardial infarction and 6
occurred 1 week later. Eighteen animals received a second
endocardial cell injection 4 weeks following the first
injection i.e. at 4 or 5 weeks (Fig. 1), as 3 animals died in
the interval period, one from congestive heart failure, and
the other two from presumed fatal arrhythmias.
Endocardial injections
Endocardial injections used fluoroscopic guidance with the
StillettoTM Endomyocardial Injection System (Boston Sci-
entific, Natick, MA) as previously described [25]. Briefly,
biplane contrast ventriculograms were used to guide the
injections into the myocardium, at the periphery of the wall
motion abnormalities. Multiple injections (8–10) of 0.1 ml
each were delivered using a 26-gauge needle.
Epicardial injections
At the time of the open thoracotomy, multiple injections
(8–10) of 0.1 ml were delivered into the peri-infarct region
of the infarction, defined as the peripheral 1 cm of dis-
coloration on the epicardial surface, using a 25-gauge
needle [25].
SPECT/CT imaging and contrast-enhanced CT imaging
Contrast enhanced CT was used to document the sites of
injection in relationship to the zone of reduced perfusion.
We have previously described the SPECT/CT imaging
protocol in detail [25]. After background correction, the
111In projection data was reconstructed with three iterations
of ordered subset expectation maximization. A volume of
interest was defined on day 0 images corresponding to
pixels with intensity C30 % of the maximum pixel inten-
sity. The number of counts in this volume at each follow-
up was used to determine the mean pixel intensity
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(MATLAB, Mathworks, Natick, MA). The mean pixel
intensity in the day 4, 10 and 15 follow-ups were used to
create in vivo time-activity curves of the 111In activity.
They were decay corrected and fit to a monoexponential
function in MATLAB and the half-life was reported in
hours (Table 1).
Statistical analysis
Statistical analysis was performed using SPSS 17.0 (SPSS
Inc., Chicago, IL). Comparison between injection tech-
niques was performed using a univariate ANOVA. Com-
parison between sustained occlusion and reperfused models
was performed using a 2-tailed independent samples t test.
Comparison between first and second injections in each
animal was performed using paired sample t-tests. Statis-
tical significance was set at a P \ 0.05 for all tests. All
values are expressed as mean ± SEM.
Results
In vitro 111In-tropolone labeling
In 39 cell labeling procedures, the average labeling effi-
ciency was 77.1 ± 1.5 %, resulting in an average dose of
radioactivity delivered per cell of 0.1 ± 0.003 Bq/cell.
Cell delivery efficiency
After each injection, the syringe and/or catheter used for
the injection were evaluated for the amount of retained
activity. For the first injection 8.4 ± 1.3 % of the activity
remained in the syringe after the epicardial injections,
while 15.7 ± 2.1 % of the activity remained in the syringe
and catheter after the endocardial injections (p = 0.02).
The ratio of activity in the heart over the total activity in
the body i.e. the myocardial retained activity, was similar
between the epicardial (56.7 ± 6.0 %) and endocardial
(59.5 ± 5.5 %) injections (p = 0.76).
SPECT imaging
Epicardial versus endocardial injection (day 0) Table 1
The clearance half-lives for cells injected into the epicar-
dium were not significantly different from cells injected
into the endocardium on the day of the infarction
(p = 0.313).
Endocardial injections: day 0 versus week 1
The clearance half-lives of the cells injected into the
endocardium on the day of infarction were similar to the
clearance half-lives of cells injected into the endocardium
1 week after the infarction (p = 0.185).
Fig. 1 Timing of injection—
EPCs labeled with 111Indium
were injected by a subepicardial
injection (n = 8) on the day of
infarction followed by
subendocardial injection at
4 weeks, b subendocardial
injection (n = 7) on the day of
infarction followed by
subendocardial injection at
4 weeks, or c subendocardial
injection at 1 week following
infarction (n = 6) followed by
subendocardial injection
4 weeks following the first.
Follow-up SPECT/CT imaging
occurred 4, 10, and 15 days
after each cell transplantation.
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Timing of injection (0–1 week vs. 4–5 weeks)
All animals received two cell injections, the first either on
the day of infarction or 1 week later, and the second
4 weeks following the first. Analysis was performed on the
clearance half-lives between the first and second injection
in each of the three categories of first injection (epicardial
injection on day 0, endocardial injection on day 0 and
endocardial injection at week 1), and separately grouping
all the early injections and comparing them to the late
(4–5 week) injections. Although the clearance half lives
comparing the smaller groups’ early versus late injections
did not approach statistical significance, when comparing
all the early injections (Day 0 and Week 1) versus late
injections, there was a trend towards a difference for the
first (n = 18, 73.6 ± 5.6 h) versus second (n = 18;
61.9 ± 3.3 h) injections (p = 0.074).
Sustained occlusion versus reperfused tissue
A comparison between sustained occlusion (n = 10) and
reperfused (n = 11) models for injection 1 revealed that
the cell clearance half-lives of 84.2 ± 9.6 and
61.6 ± 4.7 h, for the occlusion and reperfused models
respectively, were significantly different (p = 0.042), but
no significant difference for injection 2, 68.2 ± 5.0 h
versus 55.5 ± 3.3 h (p = 0.086) (Table 2). However,
when grouping all the sustained occlusion versus all the
reperfused injections, there was a significant difference for
sustained occlusion 77.1 ± 6.05 (n = 18) versus reper-
fused 59.4 ± 2.9 h (n = 21), p = 0.009.
Contrast enhanced CT
The post-contrast enhanced cardiac SPECT/CT showed
areas of hypo-perfusion in all animals indicating low blood
flow. All injections were localized within the zone of
reduced contrast towards the periphery of this zone (Fig. 2).
Discussion
Our study is the first to assess some of the factors that
affect cell residence time in a large animal model of
myocardial infarction. We have shown that endocardial and
epicardial injections have similar residence times and may
direct further research towards endocardial injections as
they are technically easier to perform clinically, although
safety issues may be a concern. Regarding the other tissue
based parameters, previous large animal studies tracked
cells under a single condition, i.e. single time of injection
or sustained occlusion/reperfusion, but not both, which is
unique to our study. Our laboratory has previously vali-
dated the technique of Indium tropolone labeling [26, 27],
for quantitative measurement of cell clearance. There are
Table 1 Cell clearance half-lives of endothelial progenitor cells
Canine Model Injection 1 Injection 2













69.5 ± 8.5 56.3 ± 4.7
Endocardial injection
(day 0)




13 S 83.62 66.33
14 90.16 74.27
15 143.9 69.49
83.8 ± 10.8 64.7 ± 3.8
Endocardial injection
(week 1)
16 R 42.11 69.25
17 40.49 *
18 83.67 48.43
19 S 41.46 *
20 90.50 96.16
21 79.12 53.72
62.9 ± 9.5 66.9 ± 10.7
Values are mean ± SEM
R reperfused myocardial infarction, S sustained occlusion myocardial
infarction
* SPECT image not acquired
Table 2 Mean cell clearance half lives of endothelial progenitor cells
in sustained occlusion and reperfused models of myocardial infarction
n Model Injection 1 Injection 2
Half-life (hours) Half-life (hours)
11 R 61.6 ± 4.7a 55.5 ± 3.3
10 S 84.2 ± 9.6 68.2 ± 5.0
Values are mean ± SEM
R reperfused myocardial infarction, S sustained occlusion myocardial
infarction, n sample size
a R versus S p = 0.042
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other methods to track cells following transplantation [30–
39], some of which have demonstrated approximately the
same range of clearance half-times seen in our study [38].
However, the status of the tissue, and cell type appear to
have a significant bearing on clearance rates, based on
work in a rat model using optical imaging [40]. Longer
clearance times for stromal cells were found if they were
(a) injected at 30 min versus 5 days, (b) transplanted into
normal versus infarcted myocardium, (c) syngeneic trans-
plants versus allogeneic and (d) treated with immunosup-
pressive therapy.
Also, the time of injection appears to have an effect as
Schachinger reported that cell retention declined as the
time elapsed since the infarct increased [41] in a clinical
study of patients ranging from 5 days to 17 years.
Endocardial injections: day 0 versus week 1
Macrophage invasion in canine myocardial infarction has a
slow sustained progression starting at 24 h, and peaking at
7 days [20]. In our study, the endocardial injections on day
0 occurred 4–5 h after coronary occlusion, before the major
infiltration of macrophages, whereas the injection at
1 week occurred at its peak. Had the radioactive debris
from dead transplanted cells been engulfed by the resident
macrophages, we would have observed an apparent pro-
longed cell clearance at 1 week. However, we found sim-
ilar clearance half-lives at day 0 and week 1 arguing
against this hypothesis.
Timing of injection (0–1 weeks vs. 4 weeks)
Each animal received two cell injections, separated by
4 weeks, with a trend towards longer half-lives with the
earlier injections. This may have been related to lower
blood flows initially with a gradual increase over time
related to augmented collateral supply. However, we did
not measure regional myocardial perfusion to validate this
hypothesis. In theory, earlier cell injections may be more
beneficial in limiting the full evolution of an infarct, but
this is also unproven. Further, providing an adequate
number of cells to culture expand and then transplant for
early injections at 1 week would be problematic, and their
safety remains a concern.
Sustained occlusion versus reperfused tissue
The residence time following transplantation into the sus-
tained animals was longer by 17.7 h on average compared
to reperfused animals. This difference would produce
approximately twice as many cells still resident at the site
of infarction at 10 days after injection (1/8th vs. 1/16th). If
treatment effect is correlated with cell residence times, this
would suggest that greater myocardial regeneration would
occur, everything else being equal. However, we did not
assess the extent of infarction or alternatively, the viability
of the infarcted/ischemic tissue in this study to make this
direct link.
Variation in cell clearance
These may be related to differences in infarct size, varia-
tions in collateral flow around the coronary artery occlu-
sion, in basal heart rate, and blood pressure between
animals. Also, the injections were targeted solely based on
wall motion abnormalities, which could be caused by
stunned, hibernating, or infarcted myocardium (viability
status was not used to direct the injections). The contrast
enhanced CT images confirmed that, in all cases, the
injections had been placed within the zone of reduced
perfusion, and generally towards its periphery.
Safety and clinical relevance
Here, we have shown that careful experiments using a large
animal model (canine) were undertaken with a relatively
Fig. 2 SPECT/CT—day 0 imaging of 111Indium labeled EPCs
transplanted in a canine heart by endocardial injection a Coronal
fused SPECT/CT image showing activity localized to the heart.
b Transaxial contrast-enhanced CT image with arrow denoting hypo-
enhanced region within the infarction, c Transaxial contrast-enhanced
CT image fused with SPECT image of transplanted EPCs. EPC
endothelial progenitor cell, SPECT/CT single photon emission
computed tomography/computed tomography
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low overall attrition rate of 6/24 (25 %), primarily from
arrhythmias, which is consistent with our experience over
the past 25 years with this model. There were no perfora-
tions. Gyongyosi has reported on the safety of early post
infarction injections in 60 patients receiving direct myo-
cardial injections at either 3–6 weeks or 3–4 months 42],
and Krause demonstrated the safety of direct endocardial
injections an average of 10.5 days after infarction [43],
with no peri-procedural complications. We have shown
here that late injections at 4–5 weeks are associated with
comparable cell clearance as for injections within the first
week.
Study limitations
The focus of this study was to determine if clinically sig-
nificant differences in transplanted cell residency time were
a function of infarct status (reperfused vs. chronic), time of
injection after infarct event or route of cell administration
(epicardial vs. endocardial). Hence protocol design was
optimized to achieve these results with a minimum number
of dogs. This was achieved by injecting each animal twice
(day 0 or 1 week followed by a second injection 4 weeks
after the first). This allowed post hoc analysis with paired
sample t-testing for increased statistical power for the same
number of animals but also introduced study limitations.
Treatment effect could not be investigated as 4 weeks is, in
our experience [44], too short a time after the first injection
to assess this. Additionally, with two injections, any
treatment effect at a remote time point e.g. 12 weeks could
not be uniquely attributable to one of the two injections.
Another concern is the potential contaminating effect of
any residual treatment response or inflammatory reaction,
of the first injection on the 4–5 week residence times.
However, on review of the data, (Table 1), there was no
consistent pattern seen from first to second injection. The
relatively small sample sizes in each group limited the size
of the effects that can be seen with statistical certainty. For
example we would have needed much larger sample sizes
(27–62 animals/group based on Cohen’s effect size for two
independent means, p \ 0.05, power = 0.80) to have
demonstrated that the differences between injection 1 and
injection 2 were significant or the differences between the
epicardial versus endocardial injections were different.
However the aim of the study was to determine if differ-
ences were large and hence would likely have an impact in
clinical application and this, we argue, was achieved.
Conclusions
The transplanted cell clearance kinetics injected on the day
of infarction, at 1 week and 4–5 weeks following
infarction showed no statistical difference, although there
was a trend to longer half-lives for the earlier injections.
Sustained occlusion infarcts, which generally are larger
than reperfused ones, and would benefit most from regen-
eration, had statistically longer cell retention times.
Although it is beyond the scope of this article to discuss in
detail, the current clinical trial evidence suggests no
prognostic benefit to delayed re-opening of a chronically
occluded coronary artery [45]. If cell residence time is
associated with treatment effect size and/or transplanted
cell proliferation, relatively greater effects would be
observed following transplantation into the peri-infarct
region of sustained occlusion infarcts.
Acknowledgments We thank Michelle Belton, Astrid Chamson-
Reig and Donna Goldhawk for assistance with cell culture, Yves
Bureau for statistical analysis and Janice DeMoor for assistance in
manuscript preparation. Financial support for this project was
received from the Heart and Stroke Foundation of Ontario, Toronto,
Ontario, the Canadian Institutes for Health Research, Ottawa, Ontario
and the Ontario Ministry of Research and Innovation. We also
acknowledge the support of Boston Scientific, Natick, Massachusetts
who provided the Stilletto catheters.
Conflict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Bloom BR (2005) Public health in transition. Sci Am 293:92–99
2. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y,
Ozono R, Masaki H, Mori Y, Iba O, Tateishi E, Kosaki A,
Shintani S, Murohara T, Imaizumi T, Iwasaka T (2001)
Implantation of bone marrow mononuclear cells into ischemic
myocardium enhances collateral perfusion and regional function
via side supply of angioblasts, angiogenic ligands, and cytokines.
Circulation 104:1046–1052
3. Kudo M, Wang YG, Wani MA, Xu MF, Ayub A, Ashraf M
(2003) Implantation of bone marrow stem cells reduces the
infarction and fibrosis in ischemic mouse heart. J Mol Cell Car-
diol 35:1113–1119
4. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J,
Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A,
Ogawa S (1999) Cardiomyocytes can be generated from marrow
stromal cells in vitro. J Clin Invest 103:697–705
5. Nishida M, Li TS, Hirata K, Yano M, Matsuzaki M, Hamano K
(2003) Improvement of cardiac function by bone marrow cell
implantation in a rat hypoperfusion heart model. Ann Thorac
Surg 75:768–773
6. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B,
Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, An-
versa P (2001) Bone marrow cells regenerate infarcted myocar-
dium. Nature 410:701–705
7. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li
T, Witzenbichler B, Schatterman G, Isner JM (1997) Isolation of
putative progenitor endothelial cells for angiogenesis. Science
275:964–967
502 Int J Cardiovasc Imaging (2013) 29:497–504
123
8. Badorff C, Brandes RP, Popp R, Rupp S, Urbich C, Aicher A,
Fleming I, Busse R, Zeiher AM, Dimmeler S (2003) Transdif-
ferentiation of blood-derived human adult endothelial progenitor
cells into functionally active cardiomyocytes. Circulation 107:
1024–1032
9. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S,
Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T
(2001) Therapeutic potential of ex vivo expanded endothelial
progenitor cells for myocardial ischemia. Circulation 103:
634–637
10. Kawamoto A, Tkebuchava T, Yamaguchi JI, Nishimura H, Yoon
YS, Milliken C, Uchida S, Masuo O, Iwaguro H, Ma H, Hanley
A, Silver M, Kearney M, Losordo DW, Isner JM, Asahara T
(2003) Intramyocardial transplantation of autologous endothelial
progenitor cells for therapeutic neovascularization of myocardial
ischemia. Circulation 107:461–468
11. Assmus B, Scha¨chinger V, Teupe C, Britten M, Lehmann R,
Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D,
Dimmeler S, Zeiher AM (2002) Transplantation of progenitor
cells and regeneration enhancement in acute myocardial infarc-
tion—(TOPCARE-AMI). Circulation 106:3009–3017
12. Britten MB, Abolmaali ND, Assmus B, Lehmann R, Honold J,
Schmitt J, Vogl TJ, Martin H, Scha¨chinger V, Dimmeler S,
Zeiher AM (2003) Transplantation of progenitor cells and
regeneration enhancement in acute myocardial infarction (TOP-
CARE-AMI): mechanistic insights from serial contrast-enhanced
magnetic resonance imaging. Circulation 108:2212–2218
13. Scha¨chinger V, Assmus B, Britten MB, Honold J, Lehmann R,
Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H,
Dimmeler S, Zeiher AM (2004) Transplantation of progenitor
cells and regeneration enhancement in acute myocardial infarc-
tion—final one-year results of the TOPCARE-AMI trial. J Am
Coll Cardiol 44:1690–1699
14. Meyer GP, Wollert KC, Lotz J, Pirr J, Rager U, Lippolt P, Hahn
A, Fichtner S, Schaefer A, Arseniev L, Ganser A, Drexler H
(2008) Intracoronary bone marrow cell transfer after myocardial
infarction: 5-year follow-up of the BOOST trial. Circulation
118:S764–S765
15. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S,
Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A,
Drexler H (2006) Intracoronary bone marrow cell transfer after
myocardial infarction—eighteen months’ follow-up data from the
randomized, controlled BOOST (BOne marrOw transfer to
enhance ST-elevation infarct regeneration) trial. Circulation
113:1287–1294
16. Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B,
Ganser A, Knapp WH, Drexler H (2005) Monitoring of bone
marrow cell homing to the infarcted human myocardium. Cir-
culation 111:2198–2202
17. Yousef M, Schannwell CM, Koestering M, Zeus T, Brehm M,
Strauer BE (2009) The BALANCE study: clinical benefit and
long-term outcome after intracoronary autologous bone marrow
cell transplantation in patients with acute myocardial infarction.
J Am Coll Cardiol 53:2262–2269
18. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur
A, Watt SM (2008) Autologous bone marrow stem cells to treat
acute myocardial infarction: a systematic review. Eur Heart J
29:1807–1818
19. Wen Y, Meng L, Xie J, Ouyang J (2011) Direct autologous bone
marrow-derived stem cell transplantation for ischemic heart dis-
ease: a meta-analysis. Expert Opin Biol Ther 11:559–567
20. Dewald O, Ren GF, Duerr GD, Zoerlein M, Klemm C, Gersch C,
Tincey S, Michael LH, Entman ML, Frangogiannis NG (2004) Of
mice and dogs: species-specific differences in the inflammatory
response following myocardial infarction. Am J Pathol 164:
665–677
21. Ziebart T, Yoon C, Trepels T, Wietelmann A, Braun T, Kiessling F,
Stein S, Grez M, Ihling C, Muhly-Reinholz M, Carmona G, Urbich
C, Zeiher AM, Dimmeler S (2008) Sustained persistence of
transplanted proangiogenic cells contributes to neovascularization
and cardiac function after ischemia. Circ Res 103:1200–1201
22. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, Palasis
M, Wilensky RL (2006) A quantitative, randomized study eval-
uating three methods of mesenchymal stem cell delivery fol-
lowing myocardial infarction. Eur Heart J 27:1114–1122
23. Hale SL, Dai W, Dow JS, Kloner RA (2008) Mesenchymal stem
cell administration at coronary artery reperfusion in the rat by two
delivery routes: a quantitative assessment. Life Sci 83:511–515
24. Hou D, Youssef EAS, Brinton TJ, Zhang P, Rogers P, Price ET,
Yeung AC, Johnstone BH, Yock PG, March KL (2005) Radio-
labeled cell distribution after intramyocardial, intracoronary, and
interstitial retrograde coronary venous delivery implications for
current clinical trials. Circulation 112:1150–1156
25. Mitchell AJ, Sabondjian E, Sykes J, Deans L, Zhu W, Lu X, Feng
Q, Prato FS, Wisenberg G (2010) Comparison of initial cell
retention and clearance kinetics after subendocardial or subepi-
cardial injections of endothelial progenitor cells in a canine
myocardial infarction model. J Nucl Med 51:413–417
26. Blackwood KJ, Lewden B, Wells GR, Sykes J, Stodilka RZ,
Wisenberg G, Prato FS (2009) In vivo SPECT quantification of
transplanted cell survival after engraftment using 111In-tropolone
in infarcted canine myocardium. J Nucl Med 50:927–935
27. Blackwood KJ, Sykes J, Deans L, Wisenberg G, Prato FS (2011)
Comparison of leakage from labeled endocardial and epicardial
cells: impact on modeling viability of cells to be transplanted into
myocardium. Int J Mol Imag 2011:472375
28. He HB, Shirota T, Yasui H, Matsuda T (2003) Canine endothelial
progenitor cell-lined hybrid vascular graft with nonthrombogenic
potential. J Thoracic Cardiovasc Surg 126:455–464
29. Blackwood KJ, Mitchell AJ, Zhu W, Feng Q, Goldhawk D,
Dhanvantari S, Wisenberg G, Prato FS (2009) Evaluation of
dose-dependent effects of 111In on canine endothelial progenitor
cells for cell tracking. Eur J Nuc Med Mol Imag 36:S239
30. Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L,
Hertenstein B, Ganser A, Knapp WH, Drexler H (2005) Moni-
toring of bone marrow cell homing into the infarcted human
myocardium. Circulation 111:2198–2202
31. Graham JJ, Foltz WD, Vaags AK, Ward MR, Yang Y, Connelly
KA, Vijayaraghavan R, Detsky JS, Hough MR, Stewart DJ,
Wright GA, Dick AJ (2010) Long-term tracking of bone marrow
progenitor cells following intracoronary injection post-myocar-
dial infarction in swine using MRI. Am J Physiol Heart Circ
Physiol 299:H125–H133
32. Kim YJ, Huh YM, Choe KO, Choi B, Choi E, Jang Y, Lee J, Suh
JS (2009) In vivo magnetic resonance imaging of injected mes-
enchymal stem cells in rat myocardial infarction; simultaneous
cell tracking and left ventricular function measurement. Int J
Cardiovasc Imaging 25:99–109
33. Kraitchman DL, Heldman AW, Atalar E, Amado LC, Martin BJ,
Pittenger MF, Hare JM, Bulte JW (2003) In vivo magnetic res-
onance imaging of mesenchymal stem cells in myocardial
infarction. Circulation 107:2290–2293
34. Amsalem Y, Mardor Y, Feinberg MS, Landa N, Miller L, Daniels D,
Ocherashvilli A, Holbova R, Yosef O, Barbash IM, Leor J (2007)
Iron-oxide labeling and outcome of transplanted mesenchymal stem
cells in the infarcted myocardium. Circulation 116:I38–I45
35. Chen IY, Greve JM, Gheysens O, Willmann JK, Rodriguez-
Porcel M, Chu P, Sheikh AY, Faranesh AZ, Paulmurugan R,
Yang PC, Wu JC, Gambhir SS (2009) Comparison of optical
bioluminescence reporter gene and superparamagnetic iron oxide
MR contrast agent as cell markers for noninvasive imaging of
cardiac cell transplantation. Mol Imag Biol 11:178–187
Int J Cardiovasc Imaging (2013) 29:497–504 503
123
36. Higuchi T, Anton M, Dumler K (2009) Combined reporter gene
PET and iron oxide MRI for monitoring survival and localization
of transplanted cells in the rat heart. J Nucl Med 50:1088–1094
37. Blackwood KJ, Kong H, Stodilka RZ, Sykes J, Wisenberg G,
Prato FS (2006) In vivo evaluation of thymidine kinase over-
expression to track canine bone marrow stromal cells using dual
isotope SPECT. Mol Imag 5:234
38. Gyo¨ngyo¨si M, Blanco J, Marian T, Tro´n L, Petneha´zy O, Petrasi
Z, Hemetsberger R, Rodriguez J, Font G, Pavo IJ, Kerte´sz I,
Balkay L, Pavo N, Posa A, Emri M, Galuska L, Kraitchman DL,
Wojta J, Huber K, Glogar D (2008) Serial noninvasive in vivo
positron emission tomographic tracking of percutaneously intra-
myocardially injected autologous porcine mesenchymal stem
cells modified for transgene reporter gene expression. Circ Car-
diovasc Imag 1:94–103
39. Stodilka RZ, Blackwood KJ, Prato FS (2006) Tracking trans-
planted cells using dual-radionuclide SPECT. Phys Med Biol
51:2619–2632
40. Westrich J, Yaeger P, He C, Stewart J, Chen R, Seleznik G,
Larson S, Wentworth B, O’Callaghan M, Wadsworth S, Akita G,
Molnar G (2010) Factors affecting residence time of mesenchy-
mal stromal cells (MSC) injected into the myocardium. Cell
Transplant 19:937–948
41. Scha¨chinger V, Aicher A, Do¨bert N, Ro¨ver R, Diener J, Fich-
tlscherer S, Assmus B, Seeger FH, Menzel C, Brenner W,
Dimmeler S, Zeiher AM (2008) Pilot trial on determinants of
progenitor cell recruitment to the infarcted human myocardium.
Circulation 118:1425–1432
42. Gyo¨ngyo¨si M, Lang I, Dettke M, Beran G, Graf S, Sochor H,
Nyolczas N, Charwat S, Hemetsberger R, Christ G, Edes I,
Balogh L, Krause KT, Jaquet K, Kuck KH, Benedek I, Hintea T,
Kiss R, Preda I, Kotevski V, Pejkov H, Zamini S, Khorsand A,
Sodeck G, Kaider A, Maurer G, Glogar D (2009) Combined
delivery approach of bone marrow mononuclear stem cells early
and late after myocardial infarction: the MYSTAR prospective,
randomized study. Nat Clin Pract Cardiovasc Med 6:70–81
43. Krause K, Jaquet K, Schneider C, Haupt S, Liozonov MV, Otte
KM, Kuck KH (2009) Percutaneous intramyocardial stem cell
injection in patients with acute myocardial infarction: first-in-
man study. Heart 95:1145–1152
44. Wisenberg G, Lekx K, Zabel P, Kong H, Mann R, Zeman PR,
Datta S, Culshaw CN, Merrifield P, Bureau Y, Wells G, Sykes J,
Prato FS (2009) Autologous myocardial stem cell therapy in a
canine model of myocardial infarction: a multi modality approach
to stem cell tracking and therapy evaluation of bone marrow
monocytes and stromal cells using SPECT and MRI. J Cardiovasc
Magn Reson 11:11
45. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR,
Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H,
Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG,
Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark
DB, Knatterud GL (2006) Occluded artery trial investigators.
Coronary intervention for persistent occlusion after myocardial
infarction. N Engl J Med 355:2395–2407
504 Int J Cardiovasc Imaging (2013) 29:497–504
123
